

• **Name:** Maria Catherine Pietanza, MD

• **Current Position:** Executive Director, Oncology Clinical Research
Merck & Co., Inc., Kenilworth, New Jersey

• **Country:** USA

• **Educational Background:**

BA, *cum laude* New York University, May 2005
New York, NY

Majors: Chemistry and Italian

MD, *cum laude* SUNY Health Science Center at Brooklyn/ Downstate, May 2001
Brooklyn, NY

• **Professional Experience:**

Assistant Member, Level I	Memorial Sloan-Kettering Cancer Center New York, NY	09/07 – 02/12
Instructor in Medicine	Weill Medical College of Cornell University New York, NY	10/07 – 03/12
Assistant Member	Memorial Sloan-Kettering Cancer Center New York, NY	02/12 – 01/16
Assistant Professor of Medicine	Weill Medical College of Cornell University New York, NY	04/12 – 01/16

• **Professional Organizations:**

American College of Physicians	2003 – present
American Society of Clinical Oncology	2004 – present
American Association for Cancer Research	2005 – present
American Society of Hematology	2006 – 2008
North American Neuroendocrine Tumor Society	2007 – present
International Association for the Study of Lung Cancer	2009 – present

• **Main Scientific Publications:**

1. Hayes SA, **Pietanza MC**, O'Driscoll D, Zheng J, Moskowitz CS, Kris MG, and Ginsberg MS. Comparison of CT Volumetric Measurement with RECIST Response in Patients with Lung Cancer. *European Journal of Radiology*. 2016;85:524-533.
2. **Pietanza MC**. Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 2016;34:1027-1029.
3. Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhman N, and **Pietanza MC**. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-pathologic Features, Treatment and Outcomes. *Clinical Lung Cancer*. 2016;17:e121-e129.
4. Rekhman N, **Pietanza MC**, Hellman MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moriera AL, Travis WD, Rudin CM, and Laydanyi M. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. *Clinical Cancer Research*. 2016;22:3618-3629.
5. **Pietanza MC**, Hellman MD, Fiore JJ, Smith-Marrone S, Basch EM, Schwartz LH, Ginsberg MS, Shouery M, Newman SK, Shaw M, Rogak LJ, Lash AE, Hilden P, and Kris MG. Phase II Study of a Non-Platinum-

- Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinoma. *Journal of Thoracic Oncology*. 2016;11:890-899.
6. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, **Pietanza MC**, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, and Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncology*. 2016;17:883-895.
 7. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, **Pietanza MC**, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, and Spigel D. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 2016;34:3740-3748.
 8. **Pietanza MC**, Litvak AM, Varghese AM, Krug LM, Fleisher M, Teitcher JB, Holodny AI, Sima CS, Woo KM, Ng KK, Won HH, Berger MF, Kris MG, and Rudin CM. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. *Lung Cancer*. 2016;99:23-30.
 9. Rudin CM, **Pietanza MC**, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, and Spigel DR. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. *Lancet Oncology*. 2017;18:42-51.
 10. Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, **Pietanza MC**, Hellman MD, Kris MG, Hsieh JJ, and Cheng EH. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. *Nature Communications*. 2017;8:16078.
 11. Wu AJ, Gillis A, Foster A, Woo K, Zhang Z, Gelblum DY, Downey RJ, Rosenzweig KE, Perez CA, **Pietanza MC**, Krug L, Rudin CM, and Rimmer A. Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. *Radiotherapy and Oncology*. 2017;125:130-135.
 12. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, **Pietanza MC**, and Garassino MC. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. *New England Journal of Medicine*. 2018; 378:2078-2092.
 13. **Pietanza MC**, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, and Byers LA. Randomized, double-blind, Phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed sensitive or refractory small cell lung cancer. *Journal of Clinical Oncology*. 2018;36:2386-2394.
 14. Huang M, **Pietanza MC**, Samkari A, Pellissier J, Burke T, Chandwani S, Kong F, and Pickard AS. Q-TWiST analysis to assess benefit-risk of pembrolizumab in patients with PD-L1-positive advanced or metastatic non-small cell lung cancer. *Pharmacoeconomics*. 2019;37:105-116.
 15. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, **Pietanza MC**, and Brahmer JR. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small cell lung cancer with PD-L1 tumor proportion score of 50% or Greater. *Journal of Clinical Oncology*. 2019;37:537-546.
 16. Rekhtman N, Desmeules P, Litvak AM, **Pietanza MC**, Santos-Zabala ML, Ni A, Montecalvo J, Chang JC, Beras A, Preeshagul IR, Sabari JK, Rudin CM, Ladanyi M, Klimstra DS, Travis WD, and Lai WC. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. *Modern Pathology*. 2019;32:1106-1122.
 17. Velcheti V, Chandwani S, Chen X, **Pietanza MC**, and Burke T. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real world analysis of time on treatment. *Immunotherapy*. 2019;11:889-901.